Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The company's lead product candidate is the ACTR707 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory CD20+ B cell non-Hodgkin lymphoma (r/r NHL).
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-945-5576
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$9.73 million
Profitability
Miscellaneous
Employees56
Next Earnings Date8/12/2019 (Estimated)
OptionableNot Optionable
Unum Therapeutics (NASDAQ:UMRX) Frequently Asked Questions
What is Unum Therapeutics' stock symbol?
Unum Therapeutics trades on the NASDAQ under the ticker symbol "UMRX."
How were Unum Therapeutics' earnings last quarter?
Unum Therapeutics Inc (NASDAQ:UMRX) issued its earnings results on Monday, May, 13th. The company reported ($0.39) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by $0.08. The firm earned $3.05 million during the quarter, compared to analysts' expectations of $3.15 million. Unum Therapeutics had a negative net margin of 373.81% and a negative return on equity of 62.24%. View Unum Therapeutics' Earnings History.
When is Unum Therapeutics' next earnings date?
What price target have analysts set for UMRX?
5 equities research analysts have issued 12 month target prices for Unum Therapeutics' shares. Their forecasts range from $10.00 to $21.00. On average, they expect Unum Therapeutics' share price to reach $17.25 in the next twelve months. This suggests a possible upside of 643.5% from the stock's current price. View Analyst Price Targets for Unum Therapeutics.
What is the consensus analysts' recommendation for Unum Therapeutics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Unum Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Unum Therapeutics.
What are Wall Street analysts saying about Unum Therapeutics stock?
Here are some recent quotes from research analysts about Unum Therapeutics stock:
- 1. HC Wainwright analysts commented, "Our price target of $18/share is based on an equally-weighted composite of: (a) $18.2/share, as a 25x multiple of taxed and diluted $7.75 discounted back to FY19 at 30% (in line with the expected PE multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $17.3/share (discounted cash flow analysis using a 18% discount rate and 2.0% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company)." (5/14/2019)
- 2. According to Zacks Investment Research, "Unum Therapeutics Inc. is a biopharmaceutical company. It focused on the development and commercialization of novel immunotherapy products of immune system to cure cancer. The company's program consists of ACTR087 rituximab, ACTR707 RITUXIMAB, ACTR087 SEA-BCMA which are in clinical stage. Unum Therapeutics Inc. is based in Cambridge, United States. " (4/26/2019)
Has Unum Therapeutics been receiving favorable news coverage?
News headlines about UMRX stock have trended somewhat positive recently, according to InfoTrie. The research group scores the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Unum Therapeutics earned a media sentiment score of 1.9 on InfoTrie's scale. They also gave headlines about the company a news buzz of 8.0 out of 10, indicating that recent news coverage is very likely to have an effect on the company's share price in the next few days. View News Stories for Unum Therapeutics.
Are investors shorting Unum Therapeutics?
Unum Therapeutics saw a drop in short interest during the month of May. As of May 15th, there was short interest totalling 912,200 shares, a drop of 6.7% from the April 15th total of 978,200 shares. Based on an average trading volume of 87,500 shares, the days-to-cover ratio is currently 10.4 days. Approximately 5.0% of the shares of the company are short sold. View Unum Therapeutics' Current Options Chain.
Who are some of Unum Therapeutics' key competitors?
Some companies that are related to Unum Therapeutics include Syros Pharmaceuticals (SYRS), Immune Design (IMDZ), Protagonist Therapeutics (PTGX), ImmunoGen (IMGN), Concert Pharmaceuticals (CNCE), Geron (GERN), XBiotech (XBIT), Zynerba Pharmaceuticals (ZYNE), Athersys (ATHX), Dynavax Technologies (DVAX), Urovant Sciences (UROV), Aratana Therapeutics (PETX), Xenon Pharmaceuticals (XENE), Verrica Pharmaceuticals (VRCA) and Synlogic (SYBX).
What other stocks do shareholders of Unum Therapeutics own?
Who are Unum Therapeutics' key executives?
Unum Therapeutics' management team includes the folowing people:
- Dr. Charles Wilson, CEO, Pres & Director (Age 54)
- Mr. Michael J. Vasconcelles, Chief Medical Officer (Age 55)
- Dr. Dario Campana, Scientific Founder & Chair of Scientific Advisory Board
- Mr. John L. Green, VP of Fin. (Age 39)
- Mr. Geoffrey Hodge, Chief Technical Officer & Sr. VP of Operations (Age 54)
When did Unum Therapeutics IPO?
(UMRX) raised $75 million in an IPO on Thursday, March 29th 2018. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Morgan Stanley and Cowen acted as the underwriters for the IPO and SunTrust Robinson Humphrey and Wedbush Securities were co-managers.
Who are Unum Therapeutics' major shareholders?
Unum Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (1.33%), Wasatch Advisors Inc. (0.84%) and Rhumbline Advisers (0.06%). Company insiders that own Unum Therapeutics stock include Liam Ratcliffe, Seth Ettenberg and Venture Fund Ix LP Atlas. View Institutional Ownership Trends for Unum Therapeutics.
Which major investors are selling Unum Therapeutics stock?
Which major investors are buying Unum Therapeutics stock?
UMRX stock was bought by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc. and Rhumbline Advisers. Company insiders that have bought Unum Therapeutics stock in the last two years include Liam Ratcliffe and Venture Fund Ix LP Atlas. View Insider Buying and Selling for Unum Therapeutics.
How do I buy shares of Unum Therapeutics?
Shares of UMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Unum Therapeutics' stock price today?
One share of UMRX stock can currently be purchased for approximately $2.32.
How big of a company is Unum Therapeutics?
Unum Therapeutics has a market capitalization of $69.88 million and generates $9.73 million in revenue each year. The company earns $-34,530,000.00 in net income (profit) each year or ($1.39) on an earnings per share basis. Unum Therapeutics employs 56 workers across the globe.View Additional Information About Unum Therapeutics.
What is Unum Therapeutics' official website?
How can I contact Unum Therapeutics?
Unum Therapeutics' mailing address is 200 CAMBRIDGE PARK DRIVE SUITE 3100, CAMBRIDGE MA, 02140. The company can be reached via phone at 617-945-5576 or via email at [email protected]
MarketBeat Community Rating for Unum Therapeutics (NASDAQ UMRX)
| Community Ranking: | | 2.4 out of 5 ( ) |
| Outperform Votes: | | 94 (Thanks for Voting!) |
| Underperform Votes: | | 99 (Thanks for Voting!) |
| Total Votes: | | 193 |
